Tamoxifen therapy in recurrent epithelial ovarian carcinoma

Sheldon A. Weiner, David S Alberts, Earl A. Surwit, John Davis, David Grosso

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients were heavily pretreated with multiple chemotherapeutic regimens (median 3). There was 1 complete responder (3.2%), 2 31 (6.4%) had a partial response, 6 31 (19.3%) had stable disease, and 22 31 (71%) had progressive disease. Twenty-four patients are dead (23 from advanced carcinoma, 1 from cardiac causes); 5 patients are alive with disease; 2 patients are lost to follow-up. Median survival of nonresponders was 7 months versus 16 months for responders (CR + PR + stable disease) (P = 0.001 life table analysis). Of the 9 responders, 7 had poorly differentiated tumors (grades 3 or 4), and 2 had moderately differentiated tumors (grade 2). Eleven patients had estrogen and progesterone receptor studies (ER, PR). No correlation between response rate and receptor status was evident. We conclude that although significant disease regression is unlikely to result from tamoxifen therapy, there may be a subset of patients who can benefit from the cytostatic properties of hormonal manipulation.

Original languageEnglish (US)
Pages (from-to)208-213
Number of pages6
JournalGynecologic Oncology
Volume27
Issue number2
DOIs
StatePublished - 1987

Fingerprint

Tamoxifen
Carcinoma
Therapeutics
Heart Neoplasms
Life Tables
Survival
Lost to Follow-Up
Cytostatic Agents
Progesterone Receptors
Estrogen Receptors
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Tamoxifen therapy in recurrent epithelial ovarian carcinoma. / Weiner, Sheldon A.; Alberts, David S; Surwit, Earl A.; Davis, John; Grosso, David.

In: Gynecologic Oncology, Vol. 27, No. 2, 1987, p. 208-213.

Research output: Contribution to journalArticle

Weiner, Sheldon A. ; Alberts, David S ; Surwit, Earl A. ; Davis, John ; Grosso, David. / Tamoxifen therapy in recurrent epithelial ovarian carcinoma. In: Gynecologic Oncology. 1987 ; Vol. 27, No. 2. pp. 208-213.
@article{3e6366984e94428288668ab6f1f7bd00,
title = "Tamoxifen therapy in recurrent epithelial ovarian carcinoma",
abstract = "Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients were heavily pretreated with multiple chemotherapeutic regimens (median 3). There was 1 complete responder (3.2{\%}), 2 31 (6.4{\%}) had a partial response, 6 31 (19.3{\%}) had stable disease, and 22 31 (71{\%}) had progressive disease. Twenty-four patients are dead (23 from advanced carcinoma, 1 from cardiac causes); 5 patients are alive with disease; 2 patients are lost to follow-up. Median survival of nonresponders was 7 months versus 16 months for responders (CR + PR + stable disease) (P = 0.001 life table analysis). Of the 9 responders, 7 had poorly differentiated tumors (grades 3 or 4), and 2 had moderately differentiated tumors (grade 2). Eleven patients had estrogen and progesterone receptor studies (ER, PR). No correlation between response rate and receptor status was evident. We conclude that although significant disease regression is unlikely to result from tamoxifen therapy, there may be a subset of patients who can benefit from the cytostatic properties of hormonal manipulation.",
author = "Weiner, {Sheldon A.} and Alberts, {David S} and Surwit, {Earl A.} and John Davis and David Grosso",
year = "1987",
doi = "10.1016/0090-8258(87)90294-0",
language = "English (US)",
volume = "27",
pages = "208--213",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Tamoxifen therapy in recurrent epithelial ovarian carcinoma

AU - Weiner, Sheldon A.

AU - Alberts, David S

AU - Surwit, Earl A.

AU - Davis, John

AU - Grosso, David

PY - 1987

Y1 - 1987

N2 - Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients were heavily pretreated with multiple chemotherapeutic regimens (median 3). There was 1 complete responder (3.2%), 2 31 (6.4%) had a partial response, 6 31 (19.3%) had stable disease, and 22 31 (71%) had progressive disease. Twenty-four patients are dead (23 from advanced carcinoma, 1 from cardiac causes); 5 patients are alive with disease; 2 patients are lost to follow-up. Median survival of nonresponders was 7 months versus 16 months for responders (CR + PR + stable disease) (P = 0.001 life table analysis). Of the 9 responders, 7 had poorly differentiated tumors (grades 3 or 4), and 2 had moderately differentiated tumors (grade 2). Eleven patients had estrogen and progesterone receptor studies (ER, PR). No correlation between response rate and receptor status was evident. We conclude that although significant disease regression is unlikely to result from tamoxifen therapy, there may be a subset of patients who can benefit from the cytostatic properties of hormonal manipulation.

AB - Thirty-seven patients with recurrent epithelial ovarian carcinoma were entered into a trial of tamoxifen therapy (10 mg BID) to determine the effect on long-term survival. Thirty-one patients were evaluable with follow-up ranging from 6 to 42 months since initiation of hormonal therapy. All patients were heavily pretreated with multiple chemotherapeutic regimens (median 3). There was 1 complete responder (3.2%), 2 31 (6.4%) had a partial response, 6 31 (19.3%) had stable disease, and 22 31 (71%) had progressive disease. Twenty-four patients are dead (23 from advanced carcinoma, 1 from cardiac causes); 5 patients are alive with disease; 2 patients are lost to follow-up. Median survival of nonresponders was 7 months versus 16 months for responders (CR + PR + stable disease) (P = 0.001 life table analysis). Of the 9 responders, 7 had poorly differentiated tumors (grades 3 or 4), and 2 had moderately differentiated tumors (grade 2). Eleven patients had estrogen and progesterone receptor studies (ER, PR). No correlation between response rate and receptor status was evident. We conclude that although significant disease regression is unlikely to result from tamoxifen therapy, there may be a subset of patients who can benefit from the cytostatic properties of hormonal manipulation.

UR - http://www.scopus.com/inward/record.url?scp=0023268835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023268835&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(87)90294-0

DO - 10.1016/0090-8258(87)90294-0

M3 - Article

VL - 27

SP - 208

EP - 213

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -